SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Photo of Philadelphia downtown city skyline
Manufacturing
TerraPower Commits $450M To Build Radioisotope Production Plant
Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.
March 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
The person launches paper airplane. Art collage.
Approvals
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
March 18, 2026
 · 
3 min read
 · 
Annalee Armstrong
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
J&J Wins FDA Nod for First Targeted Oral Anti-IL-23 Therapy for Plaque Psoriasis
Icotyde, co-developed by Johnson & Johnson and Protagonist Therapeutics, is backed by data from the Phase 3 ICONIC program, which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.
March 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is hit with an FDA warning letter regarding adverse events potentially linked to Ozempic.
March 18, 2026
 · 
1 min read
 · 
Heather McKenzie
Rocket rising moving up with growthing graph bar. Marketing time, Start up business, Business success strategy, New project. Rocket launch. Business startup concept. 3d minimal render illustration
Venture capital
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.
March 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Funding
R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease
Alongside R1 Therapeutics, Mestag Therapeutics and iDEL Therapeutics also brought in money on Tuesday, helping to push their respective cancer portfolios forward.
March 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Frog sitting atop a pile of coins pile high on table with green leaves in background, Symbol of good fortune and luck, Successful business leap and development financial and commit concept
Earnings
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales
While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established itself as the clear leader in the obesity market, in the process capturing investors’ attention and enthusiasm.
March 18, 2026
 · 
8 min read
 · 
Tristan Manalac
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
In Tight Deal Environment, Pharma May Need To Think Big
The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be time to think outside the box and shake up the industry with some consolidation.
March 18, 2026
 · 
5 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH DIA
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
This webinar introduces the DIA Artificial Intelligence Consortium, a neutral, public‑private partnership that convenes regulators, biopharmaceutical companies, academia, and technology providers, including FDA, Health Canada, MHRA, PMDA, IQVIA, Gilead, Otsuka, BeOne Medicines, Beth Israel Deaconess Medical Center–Yale School of Medicine, and others.
March 17, 2026
 · 
1 min read
 · 
BioSpace Insights
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS